World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
133
Citations
85474
World Ranking
2186
National Ranking
1234

John M. Kirkwood publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where John M. Kirkwood sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 718 publications — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

John M. Kirkwood D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where John M. Kirkwood sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 133 D-Index — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

John M. Kirkwood is affiliated with the University of Pittsburgh in the United States. Their research primarily spans the fields of Medicine as well as Biochemistry, Genetics and Molecular Biology, with a significant focus on oncology-related studies.

Their extensive publication record includes work in major scientific journals, reflecting a focus on oncology and immunology topics. The most frequent publication venues for their research are:

  • Journal of Clinical Oncology
  • Cancer Research
  • Regular and Young Investigator Award Abstracts
  • Journal for ImmunoTherapy of Cancer
  • Annals of Oncology

The primary subfields of John M. Kirkwood's research cover:

  • Oncology
  • Immunology
  • Molecular Biology
  • Ophthalmology
  • Epidemiology

The main topics addressed in their work include:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Cutaneous Melanoma Detection and Management
  • Immunotherapy and Immune Responses
  • Melanoma and MAPK Pathways
  • Ocular Oncology and Treatments
  • Immune Cell Function and Interaction

John M. Kirkwood has collaborated frequently with several co-authors, including:

  • Cindy Sander
  • Diwakar Davar
  • Ahmad A. Tarhini
  • Georgina V. Long
  • Jason J. Luke

Some notable recent publications from John M. Kirkwood's research include:

  • "Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients" (2021), published in Science
  • "Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma" (2021), published in New England Journal of Medicine
  • "Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma" (2023), published in New England Journal of Medicine
  • "Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma" (2020), published in New England Journal of Medicine
  • "Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134" (2022), published in Journal of Clinical Oncology

Among professional recognitions, John M. Kirkwood is a member of the Association of American Physicians.

Best Publications

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Final Version of 2009 AJCC Melanoma Staging and Classification

    Charles M. Balch;Jeffrey E. Gershenwald;Seng Jaw Soong;John F. Thompson

  • Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

    John M. Kirkwood;Myla Hunt Strawderman;Marc S. Ernstoff;Thomas J. Smith

  • Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

    Jeffrey E. Gershenwald;Richard A. Scolyer;Kenneth R. Hess;Vernon K. Sondak

  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf

  • Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

    Julien Fourcade;Zhaojun Sun;Mourad Benallaoua;Philippe Guillaume

  • Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

    Diwakar Davar;Amiran K. Dzutsev;John A. McCulloch;Richard R. Rodrigues

  • Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

    Antoni Ribas;Reinhard Dummer;Igor Puzanov;Ari VanderWalde

  • Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

    G. V. Long;A. Hauschild;M. Santinami;V. Atkinson

  • High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

    John M. Kirkwood;Joseph G. Ibrahim;Jeffrey A. Sosman;Vernon K. Sondak

  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

    Grant A McArthur;Paul B Chapman;Caroline Robert;James Larkin

  • High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190

    John M. Kirkwood;Joseph G. Ibrahim;Vernon K. Sondak;Jon Richards

  • Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

    Georgina V. Long;Uwe Trefzer;Michael A. Davies;Richard F. Kefford

  • TIGIT and PD-1 impair tumor antigen–specific CD8 + T cells in melanoma patients

    Joe-Marc Chauvin;Ornella Pagliano;Julien Fourcade;Zhaojun Sun

  • The role of BRAF V600 mutation in melanoma

    Paolo A. Ascierto;John M. Kirkwood;Jean Jacques Grob;Ester Simeone

  • Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

    Antoni Ribas;Richard Kefford;Margaret A. Marshall;Cornelis J.A. Punt

  • Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

    Edward L. Korn;Ping Yu Liu;Sandra J. Lee;Judith Anne W. Chapman

  • Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

    Axel Hauschild;Sanjiv S. Agarwala;Uwe Trefzer;David Hogg

  • Prognostic significance of autoimmunity during treatment of melanoma with interferon

    Michal T. Krauze;Ahmad Tarhini;Helen Gogas;John M. Kirkwood

  • Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group

    Agop Y. Bedikian;Michael Millward;Hubert Pehamberger;Robert Conry

Frequent Co-Authors

Ahmad A. Tarhini
Ahmad A. Tarhini Cleveland Clinic
Marc S. Ernstoff
Marc S. Ernstoff Roswell Park Cancer Institute
Vernon K. Sondak
Vernon K. Sondak University of South Florida
Georgina V. Long
Georgina V. Long University of Sydney
Lisa H. Butterfield
Lisa H. Butterfield University of California, San Francisco
Reinhard Dummer
Reinhard Dummer University of Zurich
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Michael B. Atkins
Michael B. Atkins Georgetown University
Keith T. Flaherty
Keith T. Flaherty Harvard University
Axel Hauschild
Axel Hauschild Kiel University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in medicine but want flexible or alternative career options? Online degrees in healthcare are rapidly expanding, offering accelerated routes into the medical field. For those aiming to enter the workforce quickly, online lpn programs provide a pathway to become a Licensed Practical Nurse in a short amount of time.

If you’re interested in mental health, advanced practice is possible through specialized tracks like online psych np programs. These programs prepare nurses for roles in psychiatric care, directly supporting patients with mental health needs.

Prefer to blend medicine with leadership? Consider pursuing a health administration degree. This credential is ideal for those who want to manage healthcare operations rather than provide direct patient care.

Advancing further, affordable graduate options such as affordable online mha programs can help you qualify for highly sought-after management roles in hospitals, clinics, or public health organizations—often with flexible online learning.

Best Scientists Citing John M. Kirkwood

Trending Scientists

Recently Published Articles